Worldwide Life Sciences R&D Pharmacovigilance Technology Solutions Assessment

This document is an IDC MarketScape report assessing vendors in the life sciences R&D pharmacovigilance technology solutions and consulting services sector for 2025. It outlines the challenges faced by the life sciences industry, including underreporting of adverse drug reactions, data integration issues, and evolving global regulations. The report details how various pharmaceutical companies are leveraging artificial intelligence to enhance pharmacovigilance processes, such as Eli Lilly's MosaicPV and AstraZeneca's social media mining for adverse drug reactions. Additionally, it discusses the vendor challenges in balancing compliance with cost pressures and the need for innovation amidst competition from generics. The report also includes criteria for vendor inclusion, emphasizing the importance of proven expertise in pharmacovigilance and technology solutions. The document concludes with advice for technology buyers in the life sciences sector, highlighting the need for strategic partnerships and investment in technology solutions to improve patient safety and compliance.